Regulation - Anti-virals, Novartis

Filter

Current filters:

Anti-viralsNovartis

Popular Filters

News briefs: Novartis drops Ruvise MAA; B-MS settlement; Germany donates to Global Fund

25-01-2013

The European Medicines Agency says it has been formally notified by Swiss drug major Novartis (NOVN:…

Anti-viralsBMS-986094Bristol-Myers SquibbFinancialLegalNovartisPharmaceuticalRare diseasesRegulationRuviseTropical diseases

UK's NICE issues draft guideline for diagnosis and management of hepatitis B

17-01-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) is currently developing…

Anti-viralsBaracludeBiotechnologyBristol-Myers SquibbEuropeGilead SciencesNovartisPharmaceuticalPreveonPricingRegulationSebivoViread

Novartis makes Tekturna label change, updates on Gilenya and stops alisporivir trial

20-04-2012

In a day of mixed news for the Swiss drug major, Novartis (NOVN: VX) said yesterday that it has updated…

alisporivirAnti-viralsCardio-vascularGilenyaNeurologicalNovartisPharmaceuticalRegulationResearchTekturna

Positive NICE news for Gilenya for MS and Incivo for hep C

16-03-2012

There was good news from the UK drugs watchdog the Institute for Health and Clinical Excellence (NICE)…

Anti-viralsEuropeGilenyaIncivoJanssen-CilagJohnson & JohnsonNeurologicalNovartisPharmaceuticalPricingRegulation

EMA recommends new Rxing info on Victrelis and warnings for aliskiren

20-02-2012

The European Medicines Agency has recommended updating the prescribing information for US drug giant…

Aliskiren TabletsAnti-viralsCardio-vascularEuropeMerck & CoNovartisPharmaceuticalRasilezRegulationTekturnaVictrelis

European Commission OKs Novartis’ Rasitrio and new label for Bristol-Myers’ Reyataz

28-11-2011

Following a positive advisory recommendation in September, the European Commission has now approved Swiss…

Anti-viralsBristol-Myers SquibbCardio-vascularEuropeNovartisPharmaceuticalRasitrioRegulationReyataz

Back to top